Bone Biologics Stock (NASDAQ:BBLG)
Previous Close
$1.24
52W Range
$1.00 - $10.56
50D Avg
$1.50
200D Avg
$2.41
Market Cap
$2.14M
Avg Vol (3M)
$2.16M
Beta
0.67
Div Yield
-
BBLG Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
BBLG Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TLIS | Talis Biomedical Corporation |
| RPID | Rapid Micro Biosystems, Inc. |
| INVO | INVO Bioscience, Inc. |
| TIVC | Tivic Health Systems, Inc. |
| NUWE | Nuwellis, Inc. |
| RSLS | ReShape Lifesciences Inc. |
| BJDX | Bluejay Diagnostics, Inc. |
| HSCS | Heart Test Laboratories, Inc. |
| MOTS | Motus GI Holdings, Inc. |
| TNON | Tenon Medical, Inc. |
| SINT | Sintx Technologies, Inc. |
| VVOS | Vivos Therapeutics, Inc. |
| NAOV | NanoVibronix, Inc. |